European journal of pharmacology · 2026
Effect of vitamin D combined with methyldopa and labetalol on hemodynamics and pregnancy outcomes in patients with severe preeclampsia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Ping, Xia Xue, Xu Ruxue, Zheng Lili
Аннотация
OBJECTIVE: This study was designed to assess the effect of vitamin D combined with methyldopa and labetalol on hemodynamics and pregnancy outcomes in patients with severe preeclampsia.
METHODS: A total of 112 patients with severe preeclampsia were enrolled and divided into a control group and a study group. The control group received conventional basic interventions, while the study group was given vitamin D (800 IU/times, 1 time/d) combined with methyldopa (0.25 g/times, 3 times/d) and labetalol (0.1 g/times, 2 times/d) on the basis of the control group. The outcomes included clinical efficacy, hemodynamic indices, nutritional and metabolic indices, placental function, and the incidence of adverse reactions and adverse pregnancy outcomes.
RESULTS: After treatment, the study group exhibited a higher total effective rate (96.43% vs 83.93%) compared to the control group. Additionally, the study group showed greater decreases in systolic blood pressure, diastolic blood pressure, systolic/diastolic ratio, and resistive index, along with an increase in pulsatility index (P < 0.05). Serum 25-hydroxyvitamin D and placental growth factor levels increased, while homocysteine, 24-h urinary protein, and soluble fms-like tyrosine kinase-1 levels decreased in the study group relative to the control group (P < 0.05). Furthermore, the study group had a lower total incidence of adverse reactions (5.36% vs 17.86%) and adverse pregnancy outcomes (3.57% vs 14.29%) than the control group (P < 0.05).
CONCLUSION: The clinical efficacy of vitamin D combined with methyldopa and labetalol in the treatment of patients with severe preeclampsia is satisfactory and improves hemodynamics and pregnancy outcomes.
METHODS: A total of 112 patients with severe preeclampsia were enrolled and divided into a control group and a study group. The control group received conventional basic interventions, while the study group was given vitamin D (800 IU/times, 1 time/d) combined with methyldopa (0.25 g/times, 3 times/d) and labetalol (0.1 g/times, 2 times/d) on the basis of the control group. The outcomes included clinical efficacy, hemodynamic indices, nutritional and metabolic indices, placental function, and the incidence of adverse reactions and adverse pregnancy outcomes.
RESULTS: After treatment, the study group exhibited a higher total effective rate (96.43% vs 83.93%) compared to the control group. Additionally, the study group showed greater decreases in systolic blood pressure, diastolic blood pressure, systolic/diastolic ratio, and resistive index, along with an increase in pulsatility index (P < 0.05). Serum 25-hydroxyvitamin D and placental growth factor levels increased, while homocysteine, 24-h urinary protein, and soluble fms-like tyrosine kinase-1 levels decreased in the study group relative to the control group (P < 0.05). Furthermore, the study group had a lower total incidence of adverse reactions (5.36% vs 17.86%) and adverse pregnancy outcomes (3.57% vs 14.29%) than the control group (P < 0.05).
CONCLUSION: The clinical efficacy of vitamin D combined with methyldopa and labetalol in the treatment of patients with severe preeclampsia is satisfactory and improves hemodynamics and pregnancy outcomes.